$3.42
-0.06-1.72%
最終更新: Oct 26, 4:00 PM
Benzinga
Benzinga
Benzinga
木曜日, 10 29
Benzinga
© 2026 Benzinga | All Rights Reserved
Verrica Pharmaceuticals (VRCA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.48 | $-0.59 | $-0.56 | $-0.97 |
| Actual | $-0.48 | $-0.41 | $-0.51 | $0.13 |
| Surprise | 0.00% | +30.5% | +8.93% | +113.4% |
| Revenue | ||||
| Estimate | $5.9M | $4.6M | $4.4M | $12.7M |
| Actual | $5.9M | $5.0M | $5.1M | $14.3M |
| Surprise | -0.22% | +10.3% | +15.9% | +13.4% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.49 | $-0.44 |
| Revenue | ||
| Consensus | $6.2M | $7.3M |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.48 | $-0.48 | 0.00 % |
| Q1 | May 12, 2026 | $-0.41 | $-0.59 | 30.5 % |
| Q4 | Mar 11, 2026 | $-0.51 | $-0.56 | 8.93 % |
| Q3 | Nov 14, 2025 | $0.13 | $-0.97 | 113.4 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $5.86M | $5.87M | -0.22 % |
| Q1 | May 12, 2026 | $5.02M | $4.56M | 10.3 % |
| Q4 | Mar 11, 2026 | $5.09M | $4.39M | 15.9 % |
| Q3 | Nov 14, 2025 | $14.34M | $12.65M | 13.4 % |